Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs

被引:32
作者
Wildner, O [1 ]
Hoffmann, D [1 ]
Jogler, C [1 ]
Überla, K [1 ]
机构
[1] Ruhr Univ Bochum, Abt Mol & Med Virol, D-44801 Bochum, Germany
关键词
replication-competent adenoviral vector; nucleoside analogs; antiadenoviral activity; herpes simplex virus-1 thymidine kinase;
D O I
10.1038/sj.cgt.7700638
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Replication-competent adenoviral vectors hold the promise to be more efficient gene delivery vehicles than their replication-deficient counterparts, but they are also associated with a higher risk for adverse effects, especially in light of the fact that there is no established effective therapy for serious, disseminated adenovirus infection. To assess whether the therapeutic options to inhibit adenoviral replication can be enhanced by expressing a suicide gene, we examined the antiadenoviral effects of 15 drugs against wild-type adenovirus type 5 (Ad5) and an Ad5-based replication-competent vector expressing herpes simplex virus-1 thymidine kinase (HSV-tk) (Ad.OW34) using a real-time polymerase chain reaction-based assay and flow cytometry. Ad5 and Ad.OW34 were highly susceptible to the fluorinated pyrimidine analogs 5-fluoro-2'-deoxyuridine (FUdR), 5-fluorouridine (FUR), and trifluorothymidine (TFT), with a mean 50% inhibitory concentration (IC50) ranging from 0.12 to 0.32 muM. The mean IC50 of ribavirin and cidofovir (CDV) for Ad5, the most frequently used drugs to treat adenovirus disease, was 6.87 and 3.19 muM, respectively. In contrast to Ad5, the Ad.OW34 vector was susceptible to (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdU, IC50 0.09 muM), ganciclovir (GCV, IC50 0.19 muM), and acyclovir (ACV, IC50 32.04 muM). Additionally, we demonstrated in an animal model that Ad.OW34 vector replication can be inhibited significantly by GCV, CDV, and TFT by 35.2, 7.7, and 3.7-fold, respectively, compared to untreated animals. The observed antiadenoviral effects were primarily not through cell killing, since the in vitro 50% cytotoxic concentrations (CC50) were more than 1000 times higher than the antiadenoviral IC50 of the drugs examined, even in cells stably expressing HSV-tk. Since for HSV-tk-dependent inhibition of adenoviral vectors, stability of HSV-tk expression is crucial, we examined Ad.OW34 vector stability, by passaging the vector 10 times serially in the presence of 10 muM GCV. The HSV-tk/GCV system neither changed the susceptibility of Ad.OW34 to GCV significantly nor detectable vector rearrangements occurred, suggesting that the system might be suitable as a fail-safe mechanism to stop adenoviral vector replication.
引用
收藏
页码:791 / 802
页数:12
相关论文
共 99 条
[81]   ADENOVIRUS REPLICATION AS AN INVITRO PROBE FOR DRUG SENSITIVITY IN HUMAN-TUMORS [J].
PARSONS, PG ;
MAYNARD, KR ;
LITTLE, JH ;
MCLEOD, GR .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1986, 22 (04) :401-409
[82]   COMPARISON OF MTT AND ATP-BASED ASSAYS FOR THE MEASUREMENT OF VIABLE CELL NUMBER [J].
PETTY, RD ;
SUTHERLAND, LA ;
HUNTER, EM ;
CREE, IA .
JOURNAL OF BIOLUMINESCENCE AND CHEMILUMINESCENCE, 1995, 10 (01) :29-34
[83]   ANTICYTOMEGALOVIRAL ACTIVITY AND SAFETY OF CIDOFOVIR IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION AND CYTOMEGALOVIRUS VIRURIA [J].
POLIS, MA ;
SPOONER, KM ;
BAIRD, BF ;
MANISCHEWITZ, JF ;
JAFFE, HS ;
FISHER, PE ;
FALLOON, J ;
DAVEY, RT ;
KOVACS, JA ;
WALKER, RE ;
WHITCUP, SM ;
NUSSENBLATT, RB ;
LANE, HC ;
MASUR, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (04) :882-886
[84]   Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells [J].
Ram, Z ;
Culver, KW ;
Oshiro, EM ;
Viola, JJ ;
DeVroom, HL ;
Otto, E ;
Long, ZF ;
Chiang, Y ;
McGarrity, GEJ ;
Muul, LM ;
Katz, D ;
Blaese, RM ;
Oldfield, EH .
NATURE MEDICINE, 1997, 3 (12) :1354-1361
[85]  
Rodriguez R, 1997, CANCER RES, V57, P2559
[86]  
Romanowski EG, 2000, INVEST OPHTH VIS SCI, V41, P460
[87]   Gene therapy for cancer: What have we done and where are we going? [J].
Roth, JA ;
Cristiano, RJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (01) :21-39
[88]   Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells [J].
Rothmann, T ;
Hengstermann, A ;
Whitaker, NJ ;
Scheffner, M ;
zur Hausen, H .
JOURNAL OF VIROLOGY, 1998, 72 (12) :9470-9478
[89]  
ROWE WP, 1953, P SOC EXP BIOL MED, V84, P570, DOI 10.3181/00379727-84-20714
[90]  
SHU S, 1985, CANCER RES, V45, P1657